Objectives: To estimate the threshold price (TP) of regorafenib in Spain to be an efficient option in the treatment of unresectable and/or metastatic gastrointestinal stromal tumors (GIST) that have progressed on imatinib and sunitinib, compared with the best supportive care (BSC). MethOds: The TP is the maximum price at which regorafenib offers an efficient incremental cost-utility ratio (ICUR) in Spain (≤ 30,000 € /QALY). A probabilistic cost-utility Markov model of GIST treatment was developed initially in Excel to estimate costs and benefits of regorafenib compared with the BSC, from a National Health System perspective, in a lifetime horizon. Efficacy (overall survival and progression-free survival) and utilities were extracted from the GRID study, and cost values (drugs, visits, monitoring, adverse events, and end-of-life costs), from Spanish databases and published data. Then, the TP was estimated by using the Solver Add-in and a cost utility analysis was performed. Results: The initial model estimated a total cost of 33,256 € (95CI: 27,324), and utility of 1.718 QALY (95CI: 1,506-1,757) with regorafenib; the estimated values of BSC were 6,546 € (95CI: 5,637-7,026) and 1.073 QALY (95CI: 0.902-1.112), respectively.The TP of regorafenib was estimated in 2.234 € , and the total cost was 25,901 € (95CI: 21,409), showing a difference compared to BSC of 19,356 € (95CI: 16,376); the ICUR was 30,000 € /QALY (95CI: 25,795). The probability of cost-effectiveness with regorafenib was 51.8%, for a willingness to pay of 30,000 € /QALY. cOnclusiOns: Below an ex-factory price of 2.234€ , the treatment with regorafenib in unresectable and/or metastatic GIST whose disease has progressed on imatinib and sunitinib represents a cost effectiveness assignation of resources. Objectives: Autologous peripheral stem cell transplantation (ASCT) with high-dose chemotherapy is a preferred treatment for non-Hodgkin's lymphoma (NHL) patients. Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G+P) is superior to G-CSF alone for stem cell mobilization (SCM) in heavily pretreated NHL patients. The main aim of this study was to perform comparative pharmacoeconomic analysis of using G+P versus G-CSF as a method for SCM. MethOds: Analysis of the published clinical trials was conducted to evaluate comparative efficacy and safety of the studied therapy options. Taking into account the hypothesis of superior effectiveness of combination G+P for SCM for pharmacoeconomic analysis was chosen "cost-utility" analysis. For this study was adopted a Markov model simulated the care process of NHL patients undergoing ASCT using data from the Washington University site of the plerixafor Phase III study (Kymes SM. et al, 2012). Direct medical costs included diagnosis, mobilization and remobilization costs, aphaeresis, CD34+ cell processing and cryopreservation. Mobilization and remobilization costs were defined to be the costs of medical procedures, resource utilization, and medications. The incremental cost-utility ratio (ICUR) was estimated. One-way sensitivity analysis was made. Results: According to published trials the combination G+P has been shown to mobilize more CD34+ cells than G-CSF alone for ASCT. Additionally, G+P mobilization resulted in more predictable days of collection, no weekend aphaeresis procedures, and no unscheduled hospital admissions. The expected lifetime cost of providing care for NHL patients using G+P was 601 294 rubles ($11 227) more than G-CSF, but they accumulated 1.75 more quality adjusted life years (QALYs) for an ICUR of 343 596 rubles ($6 415)/QALY. The one-way sensitivity analysis showed that the results are more sensitive to the variations of key model parameter, such as price of plerixafor. cOnclusiOns: Using G+P for SCM in ASCT of patients with NHL was more effective and economically justified treatment option. Objectives: Therapy of non-small cell lung cancer is a very complex clinical problem. Revealing of an optimum version of therapy requires not only the analysis of data by clinical efficiency, but also assessments of efficiency of expenses for applied medical products. Objective of research was an assessment the efficiency of expenses of Gefitinibum in patients with non-small cell lung cancer as a second line therapy. Objectives: To assess the incremental cost-effectiveness ratio (ICER) of obinutuzumab in association with chlorambucil (GClb) for CLL previously untreated patients unsuitable for full-dose fludarabine based therapy, in the Portuguese National Health Service (NHS) perspective. Comparators are rituximab in association with chlorambucil (RClb) and chlorambucil alone (Clb). MethOds: A Markov model developed by Roche was used to predict disease progression and mortality, assuming weekly cycles and a 25 years' time horizon. Pre-progression clinical data was based on CLL11 clinical trial (Goede et al.; 2015), and post-progression data based on Eichhorst et al. (2009). Utility values were obtained on Kosmas et al. (2014). Only direct medical costs were included, being resource consumption estimated through a seven Portuguese experts panel and unit costs taken from official sources. A 5% discount rate was applied to both costs and consequences. Results: In comparison to RClb, GClb use allows an increase of 0.69 life years (LY) and of 0.66 quality adjusted life years (QALY) that are associated to an additional cost of 12,472€ . When compared to Clb, the use of GClb increases clinical gains by 1.07 LY and 0.99 QALYs at an additional cost of 24,104€ . Consequently, GClb costs 18,112€ per LY and 18,948€ per QALY in comparison to RClb and 22,447€ per LY and 24,352€ per QALY in comparison to Clb. Sensitivity analysis shows that results are mainly sensitive to the extrapolation methods of pre-progression survival and to utility values. cOnclusiOns: The use of obinutuzumab in association with chlorambucil for CLL previously untreated patients that are unsuitable for full-dose fludarabine based therapy implies added costs per LY and per QALY that are generally accepted in Portugal. The cost-effectiveness ratios of obinutuzumab in association with chlorambucil (GClb) are below 25,000€ when compared both to rituximab in association with chlorambucil (RClb) and to chlorambucil alone (Clb). Objectives: This study aimed to assess the cost-effectiveness of first-line treatment of patients with cetuximab in combination with either FOLFOX or FOLFIRI with wild type rat sarcoma viral oncogene (RASwt) metastatic colorectal cancer in Belgium (B) and the Netherlands (NL) compared with treatment with FOLFOX or FOLFIRI. MethOds: A Markov model was developed to estimate the incremental cost-utility ratios (ICURs) of the following first-line treatment comparisons: cetuximab + FOLFIRI vs. FOLFIRI and cetuximab + FOLFOX vs. FOLFOX. The model was populated with trial data where possible. Only head-to-head trials were considered including cetuximab and RASwt data. Survival was estimated based on a disease modelling approach. Two versions of the model were created; one for NL and one for B. Country specific costs were included and second-and third-line treatments differed between NL and B. In line with the country's health economic guidelines, analyses were conducted from a societal perspective (NL) or a health care perspective (B). Costs were discounted with 4% (NL) or 3% (B) and effects with 1.5%. The models adopted a 20 year time-horizon. A probabilistic sensitivity analysis was conducted to account for uncertainty. Results: The ICURs for NL and B were € 86,180 and € 55,430 for cetuximab + FOLFIRI vs. FOLFIRI and € 83,151 and € 42,453 for cetuximab + FOLFOX vs. FOLFOX. Uncertainty around the ICURs was relatively small in the FOLFIRI arms and considerable in the FOLFOX arms. cOnclusiOns: NL and B have no official ICUR thresholds, but unofficial upper limits are assumed to be around € 80,000 in NL and € 45,000 in B. ICURs were close to these limits. ICURs differed strongly between NL and B. This was mainly caused by lower drug costs in B.
Objectives: To estimate the threshold price (TP) of regorafenib in Spain to be an efficient option in the treatment of unresectable and/or metastatic gastrointestinal stromal tumors (GIST) that have progressed on imatinib and sunitinib, compared with the best supportive care (BSC). MethOds: The TP is the maximum price at which regorafenib offers an efficient incremental cost-utility ratio (ICUR) in Spain (≤ 30,000 € /QALY). A probabilistic cost-utility Markov model of GIST treatment was developed initially in Excel to estimate costs and benefits of regorafenib compared with the BSC, from a National Health System perspective, in a lifetime horizon. Efficacy (overall survival and progression-free survival) and utilities were extracted from the GRID study, and cost values (drugs, visits, monitoring, adverse events, and end-of-life costs), from Spanish databases and published data. Then, the TP was estimated by using the Solver Add-in and a cost utility analysis was performed. Results: The initial model estimated a total cost of 33, 256 € (95CI: 27, 324) , and utility of 1.718 QALY (95CI: 1,506-1,757) with regorafenib; the estimated values of BSC were 6,546 € (95CI: 5,637-7,026) and 1.073 QALY (95CI: 0.902-1.112), respectively.The TP of regorafenib was estimated in 2.234 € , and the total cost was 25, 901 € (95CI: 21, 409) , showing a difference compared to BSC of 19, 356 € (95CI: 16, 376) ; the ICUR was 30,000 € /QALY (95CI: 25, 795) . The probability of cost-effectiveness with regorafenib was 51.8%, for a willingness to pay of 30,000 € /QALY. cOnclusiOns: Below an ex-factory price of 2.234€ , the treatment with regorafenib in unresectable and/or metastatic GIST whose disease has progressed on imatinib and sunitinib represents a cost effectiveness assignation of resources. Objectives: Autologous peripheral stem cell transplantation (ASCT) with high-dose chemotherapy is a preferred treatment for non-Hodgkin's lymphoma (NHL) patients. Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G+P) is superior to G-CSF alone for stem cell mobilization (SCM) in heavily pretreated NHL patients. The main aim of this study was to perform comparative pharmacoeconomic analysis of using G+P versus G-CSF as a method for SCM. MethOds: Analysis of the published clinical trials was conducted to evaluate comparative efficacy and safety of the studied therapy options. Taking into account the hypothesis of superior effectiveness of combination G+P for SCM for pharmacoeconomic analysis was chosen "cost-utility" analysis. For this study was adopted a Markov model simulated the care process of NHL patients undergoing ASCT using data from the Washington University site of the plerixafor Phase III study (Kymes SM. et al, 2012) . Direct medical costs included diagnosis, mobilization and remobilization costs, aphaeresis, CD34+ cell processing and cryopreservation. Mobilization and remobilization costs were defined to be the costs of medical procedures, resource utilization, and medications. The incremental cost-utility ratio (ICUR) was estimated. One-way sensitivity analysis was made. Results: According to published trials the combination G+P has been shown to mobilize more CD34+ cells than G-CSF alone for ASCT. Additionally, G+P mobilization resulted in more predictable days of collection, no weekend aphaeresis procedures, and no unscheduled hospital admissions. The expected lifetime cost of providing care for NHL patients using G+P was 601 294 rubles ($11 227) more than G-CSF, but they accumulated 1.75 more quality adjusted life years (QALYs) for an ICUR of 343 596 rubles ($6 415)/QALY. The one-way sensitivity analysis showed that the results are more sensitive to the variations of key model parameter, such as price of plerixafor. cOnclusiOns: Using G+P for SCM in ASCT of patients with NHL was more effective and economically justified treatment option. Objectives: To assess the incremental cost-effectiveness ratio (ICER) of obinutuzumab in association with chlorambucil (GClb) for CLL previously untreated patients unsuitable for full-dose fludarabine based therapy, in the Portuguese National Health Service (NHS) perspective. Comparators are rituximab in association with chlorambucil (RClb) and chlorambucil alone (Clb). MethOds: A Markov model developed by Roche was used to predict disease progression and mortality, assuming weekly cycles and a 25 years' time horizon. Pre-progression clinical data was based on CLL11 clinical trial (Goede et al.; 2015) , and post-progression data based on Eichhorst et al. (2009) . Utility values were obtained on Kosmas et al. (2014) . Only direct medical costs were included, being resource consumption estimated through a seven Portuguese experts panel and unit costs taken from official sources. A 5% discount rate was applied to both costs and consequences. Results: In comparison to RClb, GClb use allows an increase of 0.69 life years (LY) and of 0.66 quality adjusted life years (QALY) that are associated to an additional cost of 12,472€ . When compared to Clb, the use of GClb increases clinical gains by 1.07 LY and 0.99 QALYs at an additional cost of 24,104€ . Consequently, GClb costs 18,112€ per LY and 18,948€ per QALY in comparison to RClb and 22,447€ per LY and 24,352€ per QALY in comparison to Clb. Sensitivity analysis shows that results are mainly sensitive to the extrapolation methods of pre-progression survival and to utility values. cOnclusiOns: The use of obinutuzumab in association with chlorambucil for CLL previously untreated patients that are unsuitable for full-dose fludarabine based therapy implies added costs per LY and per QALY that are generally accepted in Portugal. The cost-effectiveness ratios of obinutuzumab in association with chlorambucil (GClb) are below 25,000€ when compared both to rituximab in association with chlorambucil (RClb) and to chlorambucil alone (Clb). Objectives: This study aimed to assess the cost-effectiveness of first-line treatment of patients with cetuximab in combination with either FOLFOX or FOLFIRI with wild type rat sarcoma viral oncogene (RASwt) metastatic colorectal cancer in Belgium (B) and the Netherlands (NL) compared with treatment with FOLFOX or FOLFIRI. MethOds: A Markov model was developed to estimate the incremental cost-utility ratios (ICURs) of the following first-line treatment comparisons: cetuximab + FOLFIRI vs. FOLFIRI and cetuximab + FOLFOX vs. FOLFOX. The model was populated with trial data where possible. Only head-to-head trials were considered including cetuximab and RASwt data. Survival was estimated based on a disease modelling approach. Two versions of the model were created; one for NL and one for B. Country specific costs were included and second-and third-line treatments differed between NL and B. In line with the country's health economic guidelines, analyses were conducted from a societal perspective (NL) or a health care perspective (B). Costs were discounted with 4% (NL) or 3% (B) and effects with 1.5%. The models adopted a 20 year time-horizon. A probabilistic sensitivity analysis was conducted to account for uncertainty. Results: The ICURs for NL and B were € 86,180 and € 55,430 for cetuximab + FOLFIRI vs. FOLFIRI and € 83,151 and € 42,453 for cetuximab + FOLFOX vs. FOLFOX. Uncertainty around the ICURs was relatively small in the FOLFIRI arms and considerable in the FOLFOX arms. cOnclusiOns: NL and B have no official ICUR thresholds, but unofficial upper limits are assumed to be around € 80,000 in NL and € 45,000 in B. ICURs were close to these limits. ICURs differed strongly between NL and B. This was mainly caused by lower drug costs in B. Objectives: Nab-paclitaxel is a solvent-free paclitaxel formulation approved for first-line treatment of patients with metastatic pancreatic cancer (MPC) in combination with gemcitabine. Treatment with nab-paclitaxel and gemcitabine has been shown to be clinically effective in an area of high unmet need. Patients treated with nab-paclitaxel and gemcitabine had an increase in median survival of 3.3 months compared to those treated with gemcitabine alone in patient subgroup with Karnofsky Performance Score 70-80. MethOds: A Markov cohort model was constructed for patients with MPC to examine the costs and outcomes of nabpaclitaxel and gemcitabine versus gemcitabine. Health outcomes were expressed in terms of life-years (LYs) and quality-adjusted life-years (QALYs) gained. Patient's disease progression over time was modeled using data from the MPACT study. An area under the curve methodology was used to characterize patients' disease status at different points in time. Parametric curves were fitted to the overall survival data, progression-free survival data and time on treatment data. Health Related Quality of Life data for each health state was sourced systematically from the literature. Resource unit costs and use were derived from local cross-sectional survey. The analysis was performed from payer's perspective in Slovak settings. Results: The base case result was an incremental cost-effectiveness ratio (ICER) of € 27,769 per QALY gained for paclitaxel albumin plus gemcitabine versus gemcitabine, based on an incremental cost of € 5,943, incremental survival of 3.3 months and incremental QALYs of 0.214. The key driver of the incremental costs was the additional drug acquisition cost of adding nab-paclitaxel to gemcitabine. cOnclusiOns: € 28 820 per QALY is defined as the upper limit for conditional reimbursement in Slovakia. Nab-paclitaxel and gemcitabine is the cost-effective option for the first-line treat-studies. Results: We estimated the indirect cost of cancer due to disability in EU at the amount of 4223.2 million EUR. However partial disability account for approx. 20-25% of this sum and reduces potential savings to the amount of 844.6-1055.8 million EUR. Further correction, taking into account the efficacy of rehabilitation programs (up to 85%), reduces this savings to 717.9-897.4 million EUR. Considering the loss of productivity due to sickness absence and presenteeism measured in cancer survivors' population (19.1% and 37.3% respectively) potential savings for EU economy due to return to work of cancer survivors with a disability are calculated at the amount of 364.2-455.2 million EUR. cOnclusiOns: Indirect cost of cancer related disability can be reduced, but probably only to a small extent. Objectives: European guidelines recommend colorectal cancer screening of average-risk population. Besides cancer, adenomas deserving surveillance through colonoscopy, are found. Our objective was to estimate the resources needed to undergo the recommended surveillance of adenomas found under a populationbased colorectal cancer screening program. MethOds: A previous discrete-event simulation model representing a colorectal cancer screening program for a target population of women and men aged 50-69 was used. The underlying conceptual model was based on the European Guidelines for both the screening process and follow-up after adenoma removal. Resources needed according to findings of the colonoscopy at screening were the following: genetic tests for polyposis; highcomplexity colonoscopies for high-risk adenomas and polyposis Objectives: This study assesses frequency of CINV events and resource utilization in patients treated with AC for solid cancers MethOds: The study evaluated a randomly selected cohort of patients from Inovalon's MORE2Research Edition claims database that includes longitudinal data from US health plans. Patients who received AC regimens on first day of each cycle in first line of therapy during last six months of 2013 were included. Total CINV events and CINV related and total hospital/ER visits were captured for cycles of interest in first line and were analyzed using chi-square to determine statistical differences between patients on NK-1 regimens and non-NK-1 regimens. Results: The study cohort consisted of 353 patients, 97% female, 60% with Commercial insurance, and 95% with breast cancer, with mean age of 53.1 and Charlson comorbidity score of 6.0. NK-1 based CINV regimens were utilized in 73% of the patients in the first chemotherapy cycle. Rescue anti-emetics were used by 53% of patients on NK-1 regimens versus 60% of patients on non NK-1 regimens. Frequency of CINV events was 41% for NK-1 versus 45% for the non NK-1 group. Frequency of CINV related ER visits was 5% in the NK-1 group versus 12% in the non NK-1 group, p= 0.03. CINV related hospitalizations were 3% in the NK-1 group versus 4% in the non-NK-1 group. Total ER visits were lower in the NK-1 group compared to the non NK-1 group, 12% versus 19%; total hospitalizations were also lower in the NK-1 group compared to the non NK-1 group, 8% versus 13%. cOnclusiOns: For patients on highly emetogenic AC based chemotherapy regimens, NK-1 treatments result in decreased rates of CINV events and resource utilization, with CINV related ER visits statistically lower. Further studies are warranted to determine if results are generalizable to other cancer regimens and diagnoses.
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PCN200 PREDICTING FUTURE NEED OF RESOURCES FOR
PCN201 EvALUATION OF RESOURCE UTILIzATON FOR CHEMOTHERAPY INDUCED NAUSEA AND vOMITING (CINv) IN PATIENTS TREATED WITH ANTHRACYCLINE+CYCLOPHOSPHAMIDE (AC) FOR SOLID CANCERS WITH AND WITHOUT Nk-1 BASED REGIMENS
PCN202 RESOURCE UTILIzATION IN PATIENTS WITH ADvANCED MELANOMA IN FRANCE
Flinois A 1 , Sassolas B 2 , Leccia M 3 , Levy-Bachelot L 4 , Godard C 5 , Montin R 4 , Bedane C 6 , Pacou M 7 gressing were 2 813 and 2 703 USD for Docetaxelum and Gefitinibum, respectively. Costs of 1 treatment course (21 days) of Pemetrexed were in 1,9 times higher than Gefitinibum. Therapy with Gefitinibum increase of life expectancy on 6 months and on 0,226 QALY in comparison with Pemetrexed. Costs of 1 month without progression for Gefitinib were in average 1,8 times less (2 699 and 5 016 USD for Gefitinib and Pemetrexed, respectively). Therapy with Gifinitib allows to decrease the direct medical costs on 19%. cOnclusiOns: Therapy with Gifinitib as the second line therapy in patients with non-small cell lung cancer is effective from clinical and economical point of view. Objectives: Reducing premature mortality is a crucial public health objective. A widely used measure of premature mortality is years of potential life lost before a given age (e.g. age 80). The aim of this study was to analyze the effect that pharmaceutical innovation had on premature cancer mortality in Portugal during the period 2002-2010. MethOds: The analysis was performed by using a differencein-differences research design based on longitudinal disease-level data, in order to investigate whether the diseases that had a larger increase in the number of new available drugs (i.e. more pharmaceutical innovation) had larger declines in years of potential life lost before age 80 in Portugal. Herein, we present the results specific for cancer disease. This methodology controls for the effects of macroeconomic trends and overall changes in the healthcare system. Official databases were used, such as the Eurostat for the premature mortality data. in Portugal was € 148,670,718. Thus, the estimated cost per life-year before age 80 gained from previous pharmaceutical innovation was € 5,580 (reduction in hospital costs due to the impact of pharmaceutical innovation on cancer morbidity were not accounted). cOnclusiOns: These findings indicate that pharmaceutical innovation contributed with a significant reduction in the premature mortality caused by cancer in Portugal. Moreover, the estimated cost per life-year is well below even the lowest estimates of the value of a life-year saved.
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PCN198 CANCER AND PREMATURE MORTALITY IN IRELAND: AN EMPLOYER'S PERSPECTIvE FOLLOWING THE FRICTION COST APPROACH
Hanly P 1 , Pearce A 2 , Sharp L 3 1 National College of Ireland, Dublin, Ireland, 2 National Cancer Registry Ireland, Cork, Ireland, 3 Newcastle University, Newcastle, UK Objectives: Cancer is the second leading cause of death in Ireland accounting for approximately 30% of all deaths. Of these, almost a third arise in those of working age. As well as the public health burden, cancer also imposes economic costs on society in general and employers in particular. This study measured the productivity costs associated with cancer-related premature mortality from an employer's perspective in Ireland. MethOds: Data was abstracted on the average annual number of cancer deaths between the ages of 15 and 64 in Ireland during 2005-2009 by 5-year age group and sex from the World Health Organization Cancer Mortality Database. The friction cost approach was used to value all premature cancer deaths (and those for the ten most common cancer sites in males and females), over a defined friction period (base-case = 79 days), by gross gender-and age-specific wages, adjusted for labour market characteristics. In sensitivity analyses estimates were adjusted for 'multiplier effects' associated with modern work practices and for changing labour market conditions. Results: The all-cancer premature mortality cost was € 14.3 million in 2009. Costs were more than two-fold higher for males than females. Base-case estimates were sensitive to changes in labour markets conditions and decreased by 42% following adjustment for increased unemployment levels (from 4.6% to 12.7%). Productivity costs were higher in settings with modern team-based working practices rising by almost 30% in the case of females (17% for males). cOnclusiOns: Employers are becoming increasingly aware of the adverse economic effects of illness. Our results reveal the magnitude of productivity costs associated with cancer-related premature mortality from an employer's perspective in Ireland. These results provide a sense of the types and magnitude of costs that are explicitly excluded from economic evaluations that fail to encompass a broader social perspective.
PCN199 POTENTIAL SAvINGS TO EU ECONOMY DUE TO RETURNING TO WORk OF CANCER SURvIvORS WITH A DISABILITY
Macioch T, Hermanowski TR Medical University of Warsaw, Warsaw, Poland Objectives: The number of cancer survivors is growing due to progression in diagnosis and treatment. Approximately half of cancer survivors are at working age, however many of them do not return to work. One of the reasons is a disability of cancer survivors. Although cancer related disability is usually more severe compared to disability due to other diseases, real-life data showed up to 85% of disabled cancer survivors may return to work after comprehensive rehabilitation programs. The aim of this study was to estimate potential savings to EU economy due to return to work of disabled cancer survivors. MethOds: Data on indirect cost of a cancer related disability were calculated based on Luengo-Fernandez at al. study and our own estimation of a contribution of disability to indirect cost related to morbidity. Disability structure i.e. percentage of a partially disabled cancer survivors, was adopted from Polish Social Insurance Institution data (we assumed that population with complete disability or inability for independent existence can't return to work). Presenteeism and absenteeism in cancer survivors were adopted from our previously published
